Colinz Laboratories Limited (BOM:531210)

Market Cap	105.42M -19.2%
Revenue (ttm)	58.40M -12.9%
Net Income	4.94M +2.4%
EPS	1.96 +2.6%
Shares Out	2.52M
PE Ratio	21.35
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,934
Average Volume	3,192
Open	45.35
Previous Close	45.30
Day's Range	43.15 - 47.49
52-Week Range	36.11 - 88.70
Beta	-0.15
RSI	33.18
Earnings Date	May 28, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Employees: 65
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531210

Financial Performance

In fiscal year 2025, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.